Induction of Migraine Aura With Cilostazol
Information source: Herlev Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Migraine With Aura; Stroke
Intervention: Cilostazol (Drug); Placebo (Drug)
Phase: Phase 0
Status: Completed
Sponsored by: Herlev Hospital Official(s) and/or principal investigator(s): Christina Kruuse, MD PhD DMSc, Principal Investigator, Affiliation: Consultant Neurologist, Dept Neurology
Summary
In a double blind placebo-controlled cross-over study the effect of cilostazol on aura
induction and endothelial response is tested in patient with migraine with aura.
Clinical Details
Official title: The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Primary outcome: Aura
Secondary outcome: MigraineEndothelial response
Detailed description:
Migraine with aura is associated to an increased risk of stroke. The mechanism behind such
increased risk is not fully understood. Cilostazol induce headache and migraine in migraine
patients and is used as secondary prevention of stroke. The effect on aura induction is not
known. We investigate the aura inducing potential of cilostazol and associated changes in
endothelial function.
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Migraine with aura
- Minimum of 2 attacks/year
Exclusion Criteria:
- Chronic tension type headache
- Cardiac arrhythmias
Locations and Contacts
Herlev Hospital, Dept Neurology, Herlev 2730, Denmark
Additional Information
Starting date: September 2014
Last updated: August 20, 2015
|